(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 April 2023 (20.04.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/061424 A1

(51) International Patent Classification:
A61K 39/395 (2006.01) *A61P 35/00* (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/CN2022/125017

(22) International Filing Date:
13 October 2022 (13.10.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/CN2021/124200
15 October 2021 (15.10.2021) CN
PCT/CN2022/118065
09 September 2022 (09.09.2022) CN

(71) Applicants *(for CN only)*: **INMAGENE BIOPHARMACEUTICALS (HANGZHOU) CO., LTD.** [CN/CN]; 2F, Building 9, Hexiang Science and Technology Center, Xiasha Road, Qiantang New Area, Hangzhou, Zhejiang 310018 (CN). **INMAGENE BIOPHARMACEUTICALS TECHNOLOGY (SHANGHAI) CO., LTD.** [CN/CN]; 5F, 310 Jingao Road, Pudong New District, Shanghai 201208 (CN). **INMAGENE BIOPHARMACEUTICALS (WUHAN) CO., LTD.** [CN/CN]; Room C310, West Building C4, Bio-Innovation Park, No. 666 Gaoxin Avenue, Donghu New Technology Development Zone, Wuhan, Hubei 430073 (CN).

(71) Applicant *(for all designated States except CN)*: **INMAGENE PTE. LTD.** [SG/SG]; 20 Emerald Hill Road, 229302 (SG).

(72) Inventors: **SUN, Qiang**; Room 1403, Building 6, Songdu Dongjun Guoji Jinwan, No. 190 Xiushui Road, Qiantang New District, Hangzhou, Zhejiang 310018 (CN). **JIN, Xionghua**; No. 4, Shamenjin Village, Yuanqiao Town, Huangyan District, Taizhou, Zhejiang 318025 (CN). **FAN, Pengcheng**; Room 1016, Building 2, Phase 1, Xingyao, Hangzhou, Zhejiang 310052 (CN). **XU, Zhihao**; Room 802, Building 20, 1225 Shangsha Road, Qiantang New District, Hangzhou, Zhejiang 310018 (CN).

(74) Agent: **JUN HE LAW OFFICES**; 20/F, China Resources Building 8 Jianguomenbei Avenue, Beijing 100005 (CN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2023/061424 A1

(54) Title: PHARMACEUTICAL FORMULATION COMPRISING ANTI-OX40 MONOCLONAL ANTIBODY

(57) Abstract: Disclosed is a pharmaceutical formulation including a monoclonal OX40 antibody, a buffer, a stabilizer, and a surfactant, which can maintain the stability under various scenarios, such as manufacturing, packaging, sub-packaging, shipping, administration, and/or storage. Also disclosed are the use of the pharmaceutical formulation in the preparation of a drug for treating OX40-associated diseases, in particular, inflammatory and/or autoimmune diseases, and a method for preparing the pharmaceutical formulation.